mitogen-activated protein kinase kinase kinase 19Genealiases: RCK · YSK4
Q-omics provides the consensus-scored MAP3K19 profile across patient tissues and cancer cell-line models. MAP3K19 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MAP3K19 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, MAP3K19 RNA expression shows 12,823 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, LUAD, and TGCT as cancer lineages where MAP3K19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP3K19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP3K19 survival associations across molecular data types. MAP3K19 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP3K19 RNA expression–survival associations across cancer types. High MAP3K19 expression shows unfavorable associations in KIRC, ACC and LGG, but favorable associations in SKCM, BLCA and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MAP3K19 RNA expression.
This table summarizes MAP3K19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MAP3K19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP3K19 shows lower tumor expression in LUAD, COAD, LUSC and THCA and higher tumor expression in BRCA and PRAD. The LUAD box plot shows higher MAP3K19 RNA expression in normal versus tumor tissue (log2 FC = −1.010, t-test p < 0.001).
This table shows molecular features associated with MAP3K19 in patient tissues and cancer cell lines. In patient samples, MAP3K19 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP3K19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
